Caroline Palavicino-Maggio

Caroline Palavicino-Maggio asked how remlifanserin is differentiated from KarXT, particularly given KarXT's upcoming Phase 3 readouts in Alzheimer's disease psychosis (ADP) this year.

Answer

Elizabeth Thompson, EVP and Head of Research and Development, highlighted that remlifanserin and KarXT employ different mechanistic approaches to psychosis, targeting different aspects of serotoninergic versus cholinergic signaling. She emphasized the importance of considering the drug profiles in an elderly, frail patient population, suggesting remlifanserin could be a good option if its safety profile remains consistent with NUPLAZID.

Caroline Palavicino-Maggio asked how remlifanserin is differentiated from COBENFY, particularly given COBENFY's upcoming phase III readouts in ADP.

Answer

Elizabeth Thompson, EVP and Head of Research and Development, highlighted mechanistic differences in addressing psychosis (serotoninergic vs. cholinergic signaling). She also noted differentiators in drug administration and the importance of a favorable safety profile for the elderly, frail patient population, suggesting remlifanserin could be a good option if its safety profile is consistent with NUPLAZID.